Randomized, Double-blind, Placebo-controlled, Dose Escalated Tolerance and Pharmacokinetic / Pharmacodynamic Studies of SY-008 Capsules Administered by Chinese Healthy Subjects
Phase of Trial: Phase I
Latest Information Update: 23 Aug 2018
At a glance
- Drugs SY 008 (Primary)
- Indications Diabetes mellitus
- Focus Adverse reactions
- Sponsors Yabao Pharmaceutical Group
- 31 Aug 2018 Biomarkers information updated
- 19 Jun 2018 Planned End Date changed from 30 Sep 2018 to 30 Nov 2018.
- 19 Jun 2018 Planned primary completion date changed from 23 Aug 2018 to 31 Oct 2018.